Control of Estrous Cycle in the Bitch and Queen (Including the Use of Progestins and GnRH Agonists)
Stefano Romagnoli, DVM, MS, PhD, DECAR
Professor, Dipartimento di Scienze Cliniche Veterinarie Facoltà di Medicina Veterinaria, Università di Padova
Legnaro (PD), Italia

PROGESTOGENS

Synthetic analogues of progesterone, also termed progestins or progestogens (PG), are pharmaceutical compounds commonly used to control the reproductive cycle of domestic animals The following PGs are commonly used in dogs and cats for temporary (starting the treatment shortly before proestrus onset) or prolonged (starting in anestrus) postponement of estrus, or for suppression of estrus (starting the treatment after proestrus onset) : medroxyprogesterone acetate (MPA), megestrol acetate (MA), proligestone (PR), chlormadinone acetate (CMA), delmadinone acetate (DMA), norethisterone acetate (NTA) and melengestrol acetate (MGA). From the clinical point of view all these product act in the same way through a block of the production and/or release of GnRH from the hypothalamus. These compounds show a variety of action on the reproductive and endocrine system (such as hyperplasia of the endometrium, hyperplasia of the mammary parechima, decreased production of adrenocorticosteroids, increased secretion of prolactin and growth hormone, insuline resistance) as well as some local skin reactions at the injection site and behavioral modification (increased appetite and weight, polydipsia, slight depression, decreased libido in males). In pregnant bitches and queens use of PGs may cause masculinization of female fetuses if administered early in pregnancy (during organogenesis) or delayed parturition if administered in the last decade of pregnancy.

Clinical considerations for a safe use of progestogens

All the above cited effects are reversible and do not generally cause problems in healthy young to adult animals treated for not too long and using the recommended dosage. In general, a treatment period of 6 months is considered adequate in most individuals, although longer treatments can also be safe provided that the female is given a rest of 1-2 months every 4-6 months. While most bitches and queens may tolerate well treatment periods of more than 6 months, animals with a preexisting disease such as subclinical diabetes, microscopic mammary lesion/tumor or cystic endometrial hyperplasia may see their condition worsen rapidly as a result of the PG treatment. The following is a series of considerations on patient selection and type of presenting complaint for which a PG treatment should or should not be used.

 Do not use long acting compounds (such as MPA or PR or any other compound marketed for long term use) prior to puberty in felines, as this may cause the queen to develop a long-lasting mammary hypertrophy which could become a life-threatening situation. In prepuberal animals it is best to use initially a short acting compound (such as MA) per os for 12 weeks and then change to a long acting PG once potential side effects have been ruled out.

 Do not treat pregnant females, as this may cause fetal developmental defects as well as delayed parturition, thereby causing fetal death in utero due to placental ageing and detachment.

 Do not treat pseudopregnant bitches. During a PG treatment clinical signs of pseudopregnancy will disappear but will recur once treatment is discontinued, and the problem may worsen.

 Do not treat a female during diestrus. The stage of the reproductive cycle should always be identified using vaginal cytology and/or serum progesterone assay, and the bitch or queen should best be treated during anestrus. Diestrus should be ruled out in felines too, as approximately 30% of queens ovulate spontaneously, maintaining thereafter a 30-45 day-long diestrus.

 Do not treat females with uterine haemorrhage. Prolonged sanguineous vulvar discharge following parturition in the bitch can be a critical problem which should either be treated with a uterine contractive drug (i.e., as ergonovine) or sent to surgery. Milder bloody vulvar discharge can be caused by uterine neoplasia, cystic endometrial hyperplasia with superimposed endometrial inflammation, pyometra, metritis. None of these conditions will benefit from administration of a progestogen.

 Do not treat diabetic patients. Although not always necessary, it would be wise to measure blood glucose before and/or after a prolonged treatment to confirm health status with regard to glucose metabolism.

 Do not use PGs in females with prolonged heat. A prolonged heat may be due to ovarian cyst(s), a granulosa cell tumor, or may be due to a split heat (in the bitch) or to a misinterpretation of normal estrous signs by the owner. For none of these categories is a progestogen treatment indicated (although in some cases an ovarian cyst may benefit from administration of a progestogen). Therefore, bitches or queens with a prolonged heat should not be treated with a progestogen, unless a diagnosis of cystic ovarian disease has been carefully confirmed and surgery or administration of GnRH or hCG are not a valid therapeutic option.

Choosing the right candidate

The ideal candidate is an adult postpuberal female in anestrus. Prepuberal females should not be treated long acting compounds because of the risk of precipitating a subclinical uterine, endocrine or mammary condition (such as diabetes, cystic endometrial hyperplasia-pyometra in the bitch or mammary hyperplasia in the queen) which are rare but have been reported in young animals. If one of the above conditions is present the administration of a long acting progestogen prior to diagnosis may pose a serious health threat on the female. A minimum database of clinical information to be gathered prior to administering a long-acting compound should include:

 collecting a thorough reproductive history to rule out occurrence of estrus within the last 1-2 months (which would mean that the female is in diestrus);

 a complete clinical exam;

 palpation of the mammary gland to rule out presence of mammary nodules;

 a vaginal smear to rule out presence of oestrus.

Table. 1 shows the suggested dosages of the most commonly used progestogen-based compounds in the bitch and queen.

Table 1. Suggested dosages of the 3 most commonly used progestogen compounds in bitches and queen for the control of estrous.

Suggested Dosage

Dog

Cat

Medroxyprogesterone
Acetate

2.5-3.0 mg/kg IM every 5 months

2.0 mg/kg IM every 5 months for the feline

Megestrol Acetate

<2.0 mg/kg administered for <2 weeks in proestrus, or <2.0 mg/kg administered for a longer duration of time in anestrus. A typical dosage for estrus suppression is 2.0 mg/kg/day for 8 consecutive days, while a typical dosage for temporary postponement is 0.5 mg/kg/day in late anestrus.

<5.0 mg/cat administered every other day for < 3 weeks or with a slower rate of administration.

Proligestone

10-33 mg/kg SC every 3, 4, 5, 5 months

10 mg/kg SC every 3, 4, 5, 5, months

ANDROGENS

Androgens are also widely used for the control of estrous cycle in dogs and cats, although less information is available on most of the active principle commercially available for veterinary use. In the male, androgens cause a block of spermatogenesis (due to degeneration of seminiferous tubular epithelium), an increase in libido, a higher incidence of priapism, and growth of prostatic tumors. In the female, the main reproductive effect of androgens is to cause suppression of ovarian activity thank to a negative feedback on the pituitary which decreases gonadotropin secretion; the ovaries of dogs treated with an androgen such as mibolerone will contain primary and secondary follicles but few that mature to ovulatory size. Androgens will also cause atrophy of mammary gland/endometrium and lactation arrest.

Mibolerone (originally marketed by Upjohn as Cheque drops®) was until recently the only androgen approved for estrus suppression in bitches in the United States. Mibolerone is not recommended for use in breeding animals by the manufacturer. The suggested dose of mibolerone is based on weight and breed of the dog with German Shepherds receiving the highest dose, 180 µg once daily per os, regardless of body weight. Mibolerone should not be administered to Bedlington Terriers. Estrus suppression can be achieved starting the treatment at least 30 days before onset of the next proestrus and for as long as estrus suppression is desired. Prolonged postponement can be achieved for up to 2 years, but the drug has been demonstrated to be safe and effective even if used for up to 5 years. Return to estrus averages about 70 days, with a range of 7 to 200 days.

There are no published reports describing fertility after treatment with mibolerone, although most bitches seem to exhibit apparently normal fertility after its use. The most commonly reported side-effect of androgens in female dogs is clitoral hypertrophy, which occurs to some degree in 15 to 20% of dogs treated with mibolerone. Other reported side-effects of androgens include creamy vaginal discharge, vaginitis, increased mounting and aggressive behaviour, anal gland inspissations, musky body odor, obesity, and epiphora. Androgens are contraindicated in potentially pregnant bitches, as they may cause masculinization of female fetuses; in prepuberal bitches, in which they may precipitate premature physeal closure, and in dogs with renal or hepatic diseases (Olson et al., 1986a). Presence of intranuclear hyaline bodies in hepatic cells and, rarely, changes in liver function tests have been described in dogs after treatment with mibolerone; clinical significance of hepatocellular changes is unknown.

Testosterone also has been described for estrus suppression in bitches. Successful regimens reported include injection of 100 mg testosterone propionate once weekly, oral treatment with 25 to 50 mg methyl-testosterone twice weekly, and subcutaneous implantation of at least 759 µg/kg. Testosterone, methyltestosterone and nandrolone are currently used with indications such as oestrus suppression, false pregnancy, lack of libido as well as with other non-reproductive indications (renal insufficiency, anemia, post-surgery etc.). Testosterone propionate (100 mg once weekly) and methyltestosterone (25-50 mg twice weekly per os) are currently marketed in some European countries for oestrus suppression. Canine false pregnancy can safely be treated with androgens as it does not recur following cessation of treatment unlike what happens with progestins.

GnRH AGONISTS

More recently subcutaneous implants of GnRH analogues have been positively tested in domestic and wild carnivores and felids. Leuprolide acetate (75 µg/kg IM every 28 days for 10 months), goserelin acetate (60 µg/kg IM every 21 days for 12 months) and more recently deslorelin acetate (one single implant of 6 mg causes lack of return to oestrus for 5-18 months) have shown promising results, especially considering that fertility is re-gained a few months following cessation of treatment. These products are not commercially available yet for veterinary use. Leuprolide is marketed in Europe as a human drug under commercial names such as Enantone®, Lucrin®, Carcinil®, Ginecrin®, Procren®, Procrin®, Prostap®. Goserelin is commercialised as Zoladex®. Deslorelin is awaiting approval from governmental authorities in Australia for veterinary use in dogsa dn cats.

References

1.  Concannon PW, Altsuzer N, Hampshire J et al. Growth hormone, prolactin and cortisol in dogs developing mammary nodules and an acromegaly-like appearance during treatment with medroxiprogestrone acetate. Endocrinology 106: 1173;1980

2.  Concannon PW, Meyers-Wallen VN. Current and proposed methods for contraception and termination of pregnancy in dogs and cats. J Amer Vet Med Assoc 1991;198:1214-1225.

3.  Court EA, Watson ADJ, Curch DB, Emslie DR. Effects of delmadinone acetate on pituitaryadrenal function, glucose tolerance and growth hormone in male dogs. Austr Vet J 76 (8): 555-560, 1998

4.  Curtis EM, Grant RP-Masculinization of female pups by progestogens. JAVMA 144: 395398, 1964

5.  Eigenmann JE, Eigenmann RY, Rijnberk A, Van der Gaag I, Zapf J, Foesch ER-Progesterone-controlled growth hormone overproduction and naturally occurring canine diabetes and acromegaly Acta Endocrinologica 104:167-176, 1983

6.  Eilts BE, Paccamonti DL, Hosgood G et al.-The use of Ally-trenbolone as a progestational agent to maintain pregnancy in ovariectomized bitches. Theriogenology 4:1237-1245, 1994

7.  Evans JM, Sutton DJ-The use of hormones, especially progestagens, to control oestrus in bitches. J Reprod Fert Suppl 39:163-173, 1989 Freshman JL, Olson PN, Amann RP, et al. The effects of methyltestosterone on reproductive function in male Greyhounds. Theriogenology 1990;33:1057-1073.

8.  Mansfield PD, Kemppainen RJ, Sartin JL-The effects of megestrol acetate treatment on plasma glucose concentration and insulin response to glucose administration in cats. JAAHA 22: 515-518, 1986

9.  Olson PN, Nett TM, Bowen RA, et al. A need for sterilization, contraceptives, and abortifacients: Abandoned and unwanted pets. Part II. Contraceptives. Comp Cont Ed 1986;8:173-177.

10. Sawada T, Tamada H, Inaba T, Mori J. Prevention of estrus in the queen with chlormadinone acetate administered orally. J Vet Med Sci 54 (5): 1061-1062, 1992

11. Scott DW, Concannon PW-Gross and microscopic changes in the skin of dogs with progestagen-induced acromegaly and elevated growth hormone levels. JAAHA 19:523-527, 1983

12. Selman PJ, Mol JA, Rutteman GR, Rijnberg A-Progestins and growth hormone excess in the dog. Acta Endocrinologica 125 (Suppl 1) 42, 1991

13. Trigg TE, Wright PJ, Armour AF, Williamson PE, Junaidi A, Martin GB, Doyle AG, Walsh J

14. -Use of a GnRH analogue implant to produce reversible long-term suppression of reproductive function in male and female domstic dogs. J Reprod Fert Suppl 57: 255261, 2001

15. Van den Broek AHM, O'Farrel VO-Suppression of adrenocortical function in dogs receiving therapeutic doses of megestrol acetate. J Small Anim Pract 35:285-288, 1994.

16. Van Os JL, Oldenkamp EP-Oestrus control in bitches with proligestone, a new progestational steroid. J Small Anim Practice 19: 521-529, 1978

17. Von Berky AG and Townsend WL. The relationship between the prevalence of uterine lesions and the use of medroxiprogesterone acetate for the canine population control. Austr Vet J 70 (7): 249-250, 1993

18. Wildt DE, Kinney GM, Seager SWJ. Reproduction control in the dog and cat: An examination and evaluation of current and proposed methods. J Amer Anim Hosp Assoc 1977;13:223-23

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Stefano Romagnoli, DVM, MS, PhD, DECAR
Professor, Dipartimento di Scienze Cliniche
Veterinarie Facoltà di Medicina Veterinaria
Università di Padova
Legnaro (PD), Italia


MAIN : Reproduction : Control of Estrous Cycle
Powered By VIN
SAID=27